Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Presents Preclinical Data from VMT-??-NET, Theranostic in Development for the Treatment and Diagnosis of Neuroendocrine Tumors, at the Pacifichem 2021 Congress
Optimized 203Pb/212Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumorsPreclinical data of VMT-??-NET demonstrated to significantly improve cell binding, tumor accumulation/retention
Source: finanznachrichten.de